Online Database of Chemicals from Around the World

(2S,4R)-N-[2-Chloro-1-[(2R,3S,4S,5R,6R)-3,4,5-Trihydroxy-6-Methylsulfanyl-Oxan-2-Yl]Propyl]-1-Methyl-4-Propyl-Pyrrolidine-2-Carboxamide
[CAS# 24696-19-3]

Suppliers
Achemica Switzerland Inquire  
+41 (24) 466-2929
contact@achemica.com
Chemical manufacturer since 2010
Interbioscreen Ltd. Russian Federation Inquire  
+7 (49) 6524-0091
screen@ibscreen.chg.ru
Chemical manufacturer
RIA International LLC USA Inquire  
+1 (973) 581-1282/
marketing@riausa.net,nj@riausa.net
Chemical distributor
TimTec USA Inquire  
+1 (302) 292-8500
info@timtec.com
Chemical manufacturer
Identification
Name (2S,4R)-N-[2-Chloro-1-[(2R,3S,4S,5R,6R)-3,4,5-Trihydroxy-6-Methylsulfanyl-Oxan-2-Yl]Propyl]-1-Methyl-4-Propyl-Pyrrolidine-2-Carboxamide
Synonyms (2S,4R)-N-[2-Chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-Trihydroxy-6-Methylsulfanyl-Tetrahydropyran-2-Yl]Propyl]-1-Methyl-4-Propyl-Pyrrolidine-2-Carboxamide; (2S,4R)-N-[2-Chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-Trihydroxy-6-(Methylthio)-2-Tetrahydropyranyl]Propyl]-1-Methyl-4-Propyl-2-Pyrrolidinecarboxamide; (2S,4R)-N-[2-Chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-Trihydroxy-6-(Methylthio)Tetrahydropyran-2-Yl]Propyl]-1-Methyl-4-Propyl-Pyrrolidine-2-Carboxamide
Molecular Structure CAS#: 24696-19-3, (2S,4R)-N-[2-Chloro-1-[(2R,3S,4S,5R,6R)-3,4,5-Trihydroxy-6-Methylsulfanyl-Oxan-2-Yl]Propyl]-1-Methyl-4-Propyl-Pyrrolidine-2-Carboxamide
Molecular Formula C18H33ClN2O5S
Molecular Weight 424.98
CAS Registry Number 24696-19-3
SMILES [C@@H]1(N(C[C@@H](C1)CCC)C)C(=O)NC([C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)C(Cl)C
InChI 1S/C18H33ClN2O5S/c1-5-6-10-7-11(21(3)8-10)17(25)20-12(9(2)19)16-14(23)13(22)15(24)18(26-16)27-4/h9-16,18,22-24H,5-8H2,1-4H3,(H,20,25)/t9?,10-,11+,12?,13+,14-,15-,16-,18-/m1/s1
InChIKey KDLRVYVGXIQJDK-NOWPCOIGSA-N
Properties
Density 1.299g/cm3 (Cal.)
Boiling point 628.077°C at 760 mmHg (Cal.)
Flash point 333.649°C (Cal.)
References
(1) Kenneth E. Thummel and Danny D. Shen. Percentage Binding in Plasma, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Bound in Plasma' (%) values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Bound in Plasma' values indicated for them have been provided in the files here. Structures (and values) for Clavulanate (22), Heparin (Extensive), Lithium (0), Mycophenolate (MPA: 97.5), Prednisolone (90-95 (<200 ng/ml), ~70(>1 microgm/ml)) and Rapacuronium (50-88) have not been provided here. In all, 280 drugs and their 'Bound in Plasma' values (%) are given in the files here.
(2) Kenneth E. Thummel and Danny D. Shen. Urinary Excretion, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023Urinary Excretion (%) values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had Urinary Excretion values indicated for them have been provided in the files here. Structures (and values) for Alteplase (t-PA) (Low), Clavulanate (43+-14), Enoxaparin (43), Epoetin alfa (<3), Etanercept (Negligible), Heparin (Negligible), Lithium (95+-15), Mycophenolate (MPA: <1), Prednisolone (26+-9), Rapacuronium (6-22) and Streptokinase (0) have not been provided here. In all, 297 drugs and their Urinary Excretion values (%) are given in the files here.
(3) Kenneth E. Thummel and Danny D. Shen. Volume of Distribution, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Volume of Distribution' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. These are in liters/kg units unless otherwise indicated. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Volume of Distribution' values indicated for them have been provided in the files here. Structures (and values) for Alteplase (t-PA) (0.10+-0.01), Clavulanate (0.21+-0.05), Enoxaparin (0.12+-0.04), Epoetin Alfa (0.033+-0.013 (0.033-0.075)), Etanercept (0.11), Filgrastim (0.15), Heparin (0.058+-0.11) +- 0.1), Infliximab (0.043). Interferon Alfa (0.40+-0.19), Interferon Beta (2.9+-1.8), Lithium (0.66+-0.16), Mycophenolate (MPA: 3.6+-4), Prednisolone (0.42+-0.11), Rapacuronium (0.2-0.5), Sargramostim (A: -, C:2(0.4-18) liters/(m.m)) and Streptokinase (0.08+-0.04) have not been provided here. In all, 284 drugs and their 'Volume of Distribution' values are given in the files here.
(4) Kenneth E. Thummel and Danny D. Shen. Peak Concentration, "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Peak-Concentrations' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. The units are indicated along with the values. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Structures (and values) for Alteplase (t-PA) (973+-133 ng/ml), Clavulanate (2.8 micro g/ml), Enoxaparin (ACLM: 145+-45 ng/ml, BCLM: 414+-87 ng/ml), Epoetin Alfa (SC: 176+-75 U/l, IP: 375+-123 U/l), Etanercept (IV:2.32 micro-g/ml, SC-SD:1.2 micro-g/ml, SC-MD 3 micro-g/ml), Filgrastim (SC: 4 and 49 ng/ml), Heparin (70+-39 ng/ml), Infliximab (118 micro-g/ml), Interferon Alfa (IV: ~13 ng/ml, IM: 2.0 (1.5-2.6) ng/ml, SC: 1.7 (1.2-2.3) ng/ml), Interferon Beta (IV: 1491+-659 IU/ml, SC: 40+-20 IU/ml), Lithium (IR: 1-2 mM, SR: 0.7-1.2 mM), Mycophenolate (MPA: 8-19 micro-g/ml), Prednisolone (458+-150 ng/ml), Rapacuronium (6-20 micro-g/ml), Sargramostim (A, IV: 5ng/ml, A, SC: 1.5 ng/ml, C, IV: 100 ng/ml, C, SC: 10 ng/ml) and Streptokinase (188+-58 IU/ml) have not been provided here. In all, 304 drugs and their 'Peak-Concentration' values are given in the files here.
(5) Kenneth E. Thummel and Danny D. Shen. Clearance , "Goodman & Gilman's The Pharmacological Basis of Therapeutics", 10/e, Ed. by Joel G. Hardman, Lee E. Limbird and Alfred Goodman Gilman, McGraw-Hill, pp. 1917-2023'Clearance' values have been taken from the Table A-II-1 given in Appendix II of the above mentioned reference. These are in (ml/min/kg) units unless otherwise indicated. Users are requested to go through the comments associated with these values, which have been given as footnotes in the table. Only drugs that had 'Clearance' values indicated for them have been provided in the files here. Structures (and values) for Alteplase (t-PA) (10+-4), Clavulanate (3.6+-1.0), Enoxaparin (0.3+-0.1), Epoetin Alfa (0.047+-0.017 (0.047-0.092)), Etanercept (0.02), Filgrastim (0.5-0.7), Heparin (1/(0.65 + 0/0.008D) +- 0.1), Interferon Alfa (2.8+-0.6), Interferon Beta (13+-5), Lithium (0.35+-0.11), Mycophenolate (MM: 120-163, MPA: 2.5+-0.4), Prednisolone (1.0+-0.16), Rapacuronium (7-11), Sargramostim (A: 420 ml/min/(m.m), C:49(15-118) ml/min/(m.m)) and Streptokinase (1.7+-0.7) have not been provided here. In all, 301 drugs and their 'Clearance' values are given in the files here.
Market Analysis Reports
List of Reports Available for (2S,4R)-N-[2-Chloro-1-[(2R,3S,4S,5R,6R)-3,4,5-Trihydroxy-6-Methylsulfanyl-Oxan-2-Yl]Propyl]-1-Methyl-4-Propyl-Pyrrolidine-2-Carboxamide
Related Products
1,1'-[(6-Phenoxy-s-triazine-2,4-diyl)dii...  7,7,9-Trimethyl-1-Oxa-4-Thiaspiro[4.5]De...  3-[(4-Tert-Butylcyclohexyl)Oxy]-1-Propan...  p-Tolyl 3-Methylcrotonate  3,4-Dihydro-4-Isopropyl-2,2-Dimethyl-7-O...  S-Benzyl-S-Phenyl-N-Tosylsulfilimine  1,10-Bis(1,3-Diphenyl-5-Oxo-2-Pyrazolin-...  4,4'-Biphenylylenebis(Trimethylammonium)...  6-Hydroxybetamethasone  Estradiol-3-Glucoside  (+)-Bicyclogermacrene  Premarrubiin  Diheptylamine  2-[2-[4-(2-Methyl-3-Phenothiazin-10-Ylpr...  2-(2-Methyl-Imidazole-1-Carbonyl)-Benzoi...